Peter Humphrey, MD, PhD, Discusses Histology and Clinical Trial Enrollment in RCC

Video

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how enrollment for specific trials in renal cell carcinoma may incorporate a patient’s tumor histology.

CancerNetwork® spoke with Peter Humphrey, MD, PhD, professor of pathology and director of Genitourinary Pathology at Yale School of Medicine in New Haven, Connecticut, about how clinicians can best identify patients with renal cell carcinoma who may be eligible to enroll on a clinical trial. Humphrey spoke about this topic at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®).

Transcript:

I can’t really speak to clinical trials, there’s so many ongoing. I think the oncologists [may] be the best doctors to speak to that. I would say that as far as trials, it is important to know that histology can influence enrollment. For example, there were trials presented [at the conference] where the enrollment in 1 trial was based upon a diagnosis of papillary renal cell carcinoma. Other times, it’s [based on] enrollment of clear cell versus non–clear cell renal cell [carcinoma]. Again, knowing the classification of renal cell carcinoma can help [physicians] better understand what the specific aim of the trial might be in targeting a specific type of renal cell carcinoma.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content